LAMP1 and neoplasm: In addition, tumor-bearing mice treated with anti-PVRIG mAb showed lower frequency of tumor-infiltrating CD8+ T cells expressing inhibitory receptor CD96 (Additional file 1: Fig. S6A) and higher frequency of tumor-infiltrating CD8+ T cells expressing NKG2D, TRAIL (Additional file 1: Fig. S6B), CD107a, GzmB (Additional file 1: Fig. S6C) and IFN-γ (Additional file 1: Fig. S6D).